Novelion Therapeutics Inc. announced preliminary unaudited consolidated earnings results for the fourth quarter and full year ended December 31, 2016. For the quarter, the company reported Net product sales of $13,574,000. Loss from operations was $16,510,000 against loss from operations of $3,811,000 a year ago. Loss from continuing operations was $20,120,000 against loss from continuing operations of $3,680,000 a year ago. Net loss was $20,120,000 against net loss of $3,680,000 a year ago. Basic and diluted continuing operations was $1.5 against basic and diluted continuing operations of $0.35 a year ago Non-GAAP net loss was $23,089,000 against non-GAAP net loss of $23,838,000 a year ago. Non-GAAP basic net loss per share was $1.72 against non-GAAP basic net loss per share of $2.26 a year ago.

For the full year, the company reported Net product sales of $13,574,000. Loss from operations was $38,857,000 against loss from operations of $23,345,000 a year ago. Loss from continuing operations was $53,070,000 against loss from continuing operations of $23,009,000 a year ago. Net loss was $53,072,000 against net loss of $23,009,000 a year ago. Basic and diluted continuing operations were $4.7 against basic and diluted continuing operations of $2.21 a year ago. Non-GAAP net loss was $136,853,000 against non-GAAP net loss of $27,360,000 a year ago. Non-GAAP basic net loss per share was $12.13 against non-GAAP basic net loss per share of $2.62 a year ago.

The company provides sales guidance for the full year 2017. For the year the company reported total net products sales of between $155 million and $165 million.